Samantha Semenkow
Stock Analyst at Citigroup
(0)
# 4834
Out of 5,291 analysts
46
Total ratings
20.00%
Success rate
-26.17%
Average return
Main Sectors:
Top Industries:
Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
---|---|---|---|---|---|---|---|
Bioage Labs | Maintains: Neutral | 7 5 | 3.83 | 30.55% | 3 | Mar 24, 2025 | |
Acelyrin | Maintains: Neutral | 6 3 | 2.6 | 15.38% | 2 | Jan 7, 2025 | |
Voyager Therapeutics | Initiates Coverage On: Buy | 12 | 3.65 | 228.77% | 1 | Dec 2, 2024 | |
argenx | Maintains: Strong Buy | 512 635 | 588.92 | 7.82% | 4 | Oct 17, 2024 | |
Allogene Therapeutic... | Maintains: Strong Buy | 7 8 | 1.55 | 416.13% | 2 | Aug 9, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 27 31 | 24.72 | 25.4% | 2 | Aug 9, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 8 15 | 1.7 | 782.35% | 2 | Aug 9, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Reinstates: Buy | 4 | 0.52 | 669.23% | 2 | Jun 3, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 10 14 | 2.35 | 495.74% | 6 | May 22, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Buy | 10 | 1.99 | 402.51% | 2 | May 16, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 16 15 | 1.25 | 1100% | 4 | May 9, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 9 12 | 4.96 | 141.94% | 2 | Apr 8, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 26 30 | 1.54 | 1848.05% | 2 | Apr 4, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 72 | 39.88 | 80.54% | 1 | Dec 8, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 46 | n/a | n/a | 1 | Dec 8, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 33 50 | 18.36 | 172.33% | 3 | Sep 27, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 60 56 | 22.19 | 152.37% | 3 | Aug 9, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 2 1 | n/a | n/a | 3 | May 18, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 6 | n/a | n/a | 1 | May 3, 2023 |